Neurometrix (NASDAQ:NURO) will be issuing its quarterly earnings data on Thursday, April 19th.
Shares of NURO opened at $1.44 on Tuesday. Neurometrix has a 52 week low of $1.20 and a 52 week high of $5.84. The firm has a market capitalization of $9.86, a PE ratio of -0.12 and a beta of 0.24.
NURO has been the subject of a number of research reports. Zacks Investment Research upgraded Neurometrix from a “sell” rating to a “hold” rating in a research note on Tuesday, January 30th. ValuEngine upgraded Neurometrix from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/17/neurometrix-nuro-set-to-announce-quarterly-earnings-on-thursday.html.
NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.